{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T20:46:26Z","timestamp":1764103586132,"version":"build-2065373602"},"reference-count":19,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Intrahepatic cholangiocarcinoma (iCCA) is a malignancy with limited treatment options in advanced stages. Recently, targeted therapies against fibroblast growth factor receptor 2 (FGFR2) fusions have emerged as a promising approach for selected patients. Tasurgratinib, a selective FGFR1\u20133 inhibitor, was approved in Japan in 2024 for second-line treatment of FGFR2 fusion-positive biliary tract cancer. We report the case of a 55-year-old female with advanced iCCA harboring an FGFR2-BICC1 fusion, who experienced a rapid clinical response to tasurgratinib following disease progression on gemcitabine, cisplatin, and durvalumab (GCD). Following the failure of GCD therapy, treatment with oral tasurgratinib was initiated at 140 mg\/day and subsequently reduced to 105 mg\/day due to Grade 2 diarrhea. Within weeks, imaging and tumor markers indicated a partial response, accompanied by a reduction in ascites, and improved performance status. The response sustained for several months without evidence of disease progression. Notably, no substantial clinical hyperphosphatemia or anorexia was observed during treatment. This is the first report to describe the real-world clinical efficacy of tasurgratinib in an iCCA patient with FGFR2-BICC1 fusion. Our findings suggest that tasurgratinib can provide a rapid and durable response with manageable toxicity in molecularly selected patients who have progressed on standard therapies.<\/jats:p>","DOI":"10.3390\/ijms26125586","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T06:11:49Z","timestamp":1749622309000},"page":"5586","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["First Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma with Tasurgratinib Following Regulatory Approval: A Case Report from Clinical Practice"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5045-8082","authenticated-orcid":false,"given":"Yuta","family":"Maruki","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan"},{"name":"Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6560-7503","authenticated-orcid":false,"given":"Chigusa","family":"Morizane","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5476-483X","authenticated-orcid":false,"given":"Mao","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan"},{"name":"Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Harai","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikuni","family":"Nagashio","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0394-6876","authenticated-orcid":false,"given":"Susumu","family":"Hijioka","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-807X","authenticated-orcid":false,"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Woods, E., Le, D., Jakka, B.K., and Manne, A. (2022). Changing landscape of systemic therapy in biliary tract cancer. Cancers, 14.","DOI":"10.3390\/cancers14092137"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/jhbp.1219","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- Mitsuba)","volume":"30","author":"Ioka","year":"2023","journal-title":"J. Hepato-Bil. Pancreat. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Oh, D.-Y., Ruth He, A., Qin, S., Chen, L.-T., Okusaka, T., Vogel, A., Kim, J.W., Suksombooncharoen, T., Ah Lee, M., and Kitano, M. (2022). Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid., 1.","DOI":"10.1056\/EVIDoa2200015"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: Ready for \u201cprime time\u201d in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study","volume":"21","author":"Sahai","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40265-025-02153-5","article-title":"Tasurgratinib Succinate: First Approval","volume":"85","author":"Lamb","year":"2025","journal-title":"Drugs"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Furuse, J., Jiang, B., Kuwahara, T., Satoh, T., Ma, X., Yan, S., Zhao, H.-T., Ikeda, M., Cui, T., and Sasaki, T. (2024). Pivotal Single-Arm, Phase 2 Trial of Tasurgratinib for Patients with Fibroblast Growth Factor Receptor (FGFR)-2 Gene Fusion-Positive Cholangiocarcinoma (CCA). J. Clin. Oncol., 45.","DOI":"10.1200\/JCO.2024.42.3_suppl.471"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1007\/s10147-024-02616-x","article-title":"Clinical utility of a comprehensive genomic profiling test for patient with advanced biliary tract cancer","volume":"29","author":"Inada","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"102170","DOI":"10.1016\/j.ctrv.2021.102170","article-title":"Targeting FGFR inhibition in cholangiocarcinoma","volume":"95","author":"Goyal","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: Clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Wang, G., Du, L., Zhao, J., Pan, L., Zhang, G., Wang, F., and Liu, R. (2023). Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1124482"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.32074\/1591-951X-859","article-title":"FGFR2 testing in cholangiocarcinoma: Translating molecular studies into clinical practice","volume":"115","author":"Angerilli","year":"2023","journal-title":"Pathologica"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/jjco\/hyab029","article-title":"Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma","volume":"51","author":"Tsujie","year":"2021","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00535-024-02175-y","article-title":"FGFR2 fusions assessed by NGS, FISH, and immunohistochemistry in intrahepatic cholangiocarcinoma","volume":"60","author":"Cao","year":"2025","journal-title":"J. Gastroenterol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/12\/5586\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:49:59Z","timestamp":1760032199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/12\/5586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":19,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["ijms26125586"],"URL":"https:\/\/doi.org\/10.3390\/ijms26125586","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2025,6,11]]}}}